ArticleInfection and immunity2015
Blocking yersiniabactin import attenuates extraintestinal pathogenic Escherichia coli in cystitis and pyelonephritis and represents a novel target to prevent urinary tract infection.
Article in Infection and immunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 54 citations in OpenAlex.
- From inflammation to fibrosis and cancer: the emerging role of AIEC-derived metabolites in intestinal disease progression.Experimental & molecular medicine · 2026Review
- Transcriptional changes related to metabolic and iron acquisition strategies of avian pathogenicFrontiers in cellular and infection microbiology · 2026Article
- Avian PathogenicVeterinary sciences · 2025Review
- Uropathogenic Escherichia coli wield enterobactin-derived catabolites as siderophores.The Journal of biological chemistry · 2024Article
- UropathogenicbioRxiv : the preprint server for biology · 2023Article
- Genomics and pathotypes of the many faces of Escherichia coli.FEMS microbiology reviews · 2022Article
- "Omics" Technologies - What Have They Told Us About UropathogenicFrontiers in cellular and infection microbiology · 2022Review
- Microenvironmental Factors that Shape Bacterial Metabolites in Inflammatory Bowel Disease.Frontiers in cellular and infection microbiology · 2022Review
- Copper Homeostatic Mechanisms and Their Role in the Virulence of Escherichia coli and Salmonella enterica.EcoSal Plus · 2021Review
- Differences of virulence factors, and antimicrobial susceptibility according to phylogenetic group in uropathogenic Escherichia coli strains isolated from Korean patients.Annals of clinical microbiology and antimicrobials · 2021Article
- Yersiniabactin contributes to overcoming zinc restriction duringProceedings of the National Academy of Sciences of the United States of America · 2021Article
- Article
- Iron Acquisition of Urinary Tract InfectionMicroorganisms · 2021Article
- Copper primes adaptation of uropathogenic Escherichia coli to superoxide stress by activating superoxide dismutases.PLoS pathogens · 2020Article
- Metabolomics Study on Pathogenic and Non-pathogenicMetabolites · 2020Article
- Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies.Nature reviews. Microbiology · 2020Review
- d-Mannose Treatment neither Affects UropathogenicMolecules (Basel, Switzerland) · 2020Article
- Signaling Natural Products from Human Pathogenic Bacteria.ACS infectious diseases · 2020Review
- Yersiniabactin-Producing Adherent/Invasive Escherichia coli Promotes Inflammation-Associated Fibrosis in GnotobioticInfection and immunity · 2019Article
- UTI patients have pre-existing antigen-specific antibody titers against UTI vaccine antigens.Vaccine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The emergence and spread of extended-spectrum beta-lactamases and carbapenemases among common bacterial pathogens are threatening our ability to treat routine hospital- and community-acquired infections. With the pipeline for new antibiotics virtually empty, there is an urgent need to develop novel therapeutics. Bacteria require iron to establish infection, and specialized pathogen-associated iron acquisition systems like yersiniabactin, common among pathogenic species in the family Enterobacteriaceae, including multidrug-resistant Klebsiella pneumoniae and pathogenic Escherichia coli, represent potentially novel therapeutic targets. Although the yersiniabactin system was recently identified as a vaccine target for uropathogenic E. coli (UPEC)-mediated urinary tract infection (UTI), its contribution to UPEC pathogenesis is unknown. Using an E. coli mutant (strain 536ΔfyuA) unable to acquire yersiniabactin during infection, we established the yersiniabactin receptor as a UPEC virulence factor during cystitis and pyelonephritis, a fitness factor during bacteremia, and a surface-accessible target of the experimental FyuA vaccine. In addition, we determined through transcriptome sequencing (RNA-seq) analyses of RNA from E. coli causing cystitis in women that iron acquisition systems, including the yersiniabactin system, are highly expressed by bacteria during natural uncomplicated UTI. Given that yersiniabactin contributes to the virulence of several pathogenic species in the family Enterobacteriaceae, including UPEC, and is frequently associated with multidrug-resistant strains, it represents a promising novel target to combat antibiotic-resistant infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.